Human GPRC5D-VLP (Full Length) Protein, Fluorescent
保质期:
12个月
供应商:
北京义翘神州科技股份有限公司
保存条件:
-20℃ to -80℃
规格:
20 µg/100 µg/500 µg
规格:
20 µg
产品价格:
¥5400.0
规格:
100 µg
产品价格:
¥10800.0
规格:
500 µg
产品价格:
¥34200.0
内毒素< 1.0 EU per μg protein as determined by the LAL method.
生物活性Immobilized Human GPRC5D-VLP(Full Length) Protein, Fluorescent (Cat: 24447-HNAH1) at 5 μg/mL (100 μL/well) can bind Anti-Human GPRC5D Antibody, Human IgG1the EC50 is 5-60ng/mL.
蛋白构建A DNA sequence encoding the human GPRC5D (Q9NZD1) (Met1-Val345) was expressed. This protein carries a GFP tag.
表达宿主HEK293 Cells
种属Human
预测 N 端Met 1
分子量The recombinant human GPRC5D consists of 587 amino acids and has a predicted molecular mass of 65.81 kDa.
缓冲液Supplied as sterile 50mM Hepes, 150mM NaCl, 10% Trehalose, pH 7.2.
Please contact us for any concerns or special requirements.
Please refer to the specific buffer information in the hard copy of CoA.
运输方式It is supplied and shipped as liquid with dry ice.
稳定性 & 储存条件Samples are stable for up to twelve months from date of receipt at -70℃. Store it under sterile conditions at -70℃ or lower. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
GPRC5D Protein, Human, Recombinant, Fluorescent, VLP: 别称
GPRC5D Protein, Human
GPRC5D 背景信息
Orphan G-protein-coupled receptor family C group 5 member D (GPRC5D) has seven transmembrane segments forming the core of the receptor, as well as an intracellular C-tail and an extracellular N-terminal domain. GPRC5D is highly and selectively expressed on the surface of CD138+ multiple myeloma (MM) cells, whereas in normal tissues, a much lower expression is limited to plasma cells and certain hard keratinizing tissues. This makes GPRC5D a promising marker for monitoring tumor load and a target antigen for MM-specific T cell-engaging therapies such as bispecific antibodies and CAR-T cells.
1. Eric L. Smith, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 2019. 2. Christie, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 2021. 3. Tatsushi Kodama, et al. Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma. Mol Cancer Ther 1 September 2019.